ACAD is no longer the kind of biotech where everything hangs on a single trial. The sharper question is whether NUPLAZID and DAYBUE can fund a third CNS franchise before concentration, payer pressure, and pipeline risk catch up.
ACADIA (ACAD): two drugs, $1.25 billion guidance, and one Alzheimer readout that can change the stock
NASDAQACADCoverage BootstrapBiopharma
Thesis summary
ACAD is no longer the kind of biotech where everything hangs on a single trial. The sharper question is whether NUPLAZID and DAYBUE can fund a third CNS franchise before concentration, payer pressure, and pipeline risk catch up.
View article
Discuss the thesis
0 commentsCommenting requires active membershipBecome a member
Attack the thesis, not the person.Add evidence when challenging claims.No pump, spam, or low-effort comments.
No comments yet. Start the discussion with evidence, a question, or a bear case.